Increased Expression of Tumor Proliferation Genes in Hispanic Women with Early-Stage Breast Cancer
暂无分享,去创建一个
Zhezhen Jin | J. Sparano | H. Hibshoosh | Antai Wang | M. Maurer | H. Greenlee | K. Crew | D. Hershman | Yifan Tu | E. Andreopoulou | K. Kalinsky | E. Lim | A. Desai
[1] Mutsuko Ouchi,et al. BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition. , 2015, The Journal of Biological Chemistry.
[2] P. Porter,et al. Body mass index, tumor characteristics, and prognosis following diagnosis of early-stage breast cancer in a mammographically screened population , 2012, Cancer Causes & Control.
[3] E. Perez,et al. Obesity at diagnosis is associated with inferior outcomes in hormone receptor‐positive operable breast cancer , 2012, Cancer.
[4] J. Rahnenführer,et al. Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients , 2012, BMC Cancer.
[5] H. Selby,et al. Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models , 2012, Clinical Cancer Research.
[6] Deepa Naishadham,et al. Cancer statistics for Hispanics/Latinos, 2012 , 2012, CA: a cancer journal for clinicians.
[7] Stephen C. Peiper,et al. Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells , 2012, Breast Cancer Research and Treatment.
[8] Charles M. Perou,et al. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. , 2012, Journal of the National Cancer Institute.
[9] L. Butler,et al. Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors , 2012, Cell cycle.
[10] W. Miller,et al. Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score , 2011, British Journal of Cancer.
[11] C. Cohen,et al. Proliferation (Ki-67 and Phosphohistone H3) and Oncotype DX Recurrence Score in Estrogen Receptor-positive Breast Cancer , 2011, Applied immunohistochemistry & molecular morphology : AIMM.
[12] S. Ooi,et al. Disparities in breast cancer characteristics and outcomes by race/ethnicity , 2011, Breast Cancer Research and Treatment.
[13] M. Hammond,et al. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] M. Coory,et al. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis , 2010, Breast Cancer Research and Treatment.
[15] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.
[16] G. Hortobagyi,et al. Potential biologic causes of the racial survival disparity in adjuvant trials of ER-positive breast cancer. , 2010 .
[17] M. Piccart-Gebhart,et al. Value of Ki67 in breast cancer: the debate is still open. , 2010, The Lancet. Oncology.
[18] Jack Cuzick,et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] L. Pustilnik,et al. PF-03814735, an Orally Bioavailable Small Molecule Aurora Kinase Inhibitor for Cancer Therapy , 2010, Molecular Cancer Therapeutics.
[20] K. Gelmon,et al. Ki67 in breast cancer: prognostic and predictive potential. , 2010, The Lancet. Oncology.
[21] M. Cronin,et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Michael M. Engelgau,et al. Prevalence of Diabetes and Impaired Fasting Glucose in Adults in the U.S. Population , 2006, Diabetes Care.
[23] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[24] K. Malone,et al. Differences in breast cancer stage, treatment, and survival by race and ethnicity. , 2003, Archives of internal medicine.
[25] P. Porter,et al. Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma , 2001, Cancer.
[26] G. Bevilacqua,et al. Cyclins of phases G1, S and G2/M are overexpressed in aneuploid mammary carcinomas. , 2000, Cytometry.
[27] F. Gilliland,et al. Breast cancer survival among New Mexico Hispanic, American Indian, and non-Hispanic white women (1973-1992). , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[28] P. Tartter,et al. Ethnic differences in risk and prognostic factors for breast cancer , 1995, Cancer.
[29] G M Clark,et al. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. , 1994, Journal of the National Cancer Institute.
[30] A. Jemal,et al. Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.
[31] Robert B Livingston,et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. , 2010, The Lancet. Oncology.
[32] M. Beydoun,et al. The obesity epidemic in the United States--gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. , 2007, Epidemiologic reviews.